Work Here?
Overview
Revalia Bio uses an ex vivo human organ research platform to provide contract research services for the biopharmaceutical industry. The platform lets researchers study human organs outside the body in a controlled setting, enabling evaluation of drug targets, optimization of lead compounds, and preclinical development across diseases like cancer, cardiovascular, and infectious diseases. Unlike traditional models that rely on non-human systems, Revalia Bio focuses on human organ tissue to generate data that can faster inform drug development. The company differentiates itself through its specialized ex vivo organ platform and services (target validation, lead optimization, preclinical studies) offered as contract research. Its goal is to shorten the drug development timeline and reduce costs by providing human-organ–based testing to pharmaceutical and biotech clients.
About Revalia Bio
Industries
Data & Analytics
Consulting
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Seed
Total Funding
$14.5M
Headquarters
New Haven, Connecticut
Founded
2022
Get referred to Revalia Bio
See people who can refer or advise you
Simplify's Take
What believers are saying
- Revalia said it quadrupled revenue since 2023 and signed two top pharma customers.
- The December 2025 ARPA-H award brings up to $26.7 million and government validation.
- FDA’s April 2025 animal-testing phaseout directly supports Revalia’s human-relevant testing platform.
What critics are saying
- Top pharma customers remain unnamed, making revenue concentration and renewal risk hard to judge.
- Revalia’s platform depends on scarce donor organs and complex logistics, limiting scale through 2027.
- If FDA adoption stalls after 2025, pharma returns to cheaper CROs and animal-testing incumbents.
What makes Revalia Bio unique
- Revalia’s Human Data Trials use donated human organs, not animal models, for preclinical testing.
- The company combines whole-organ perfusion, organoids, and organ-on-chip data into one translational stack.
- ARPA-H’s December 2025 CATALYST contract made Revalia a technical lead in human-first drug modeling.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$14.5M
Above
Industry Average
Funded Over
1 Rounds
Industry standards
Benefits
Flexible Work Hours
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Wellness Program
Paid Sick Leave
Paid Vacation
Growth & Insights and Company News
6 month growth
↓ -5%1 year growth
↓ -5%2 year growth
↓ -5%Revalia Bio has been awarded a contract worth up to $26.7 million from the Advanced Research Projects Agency for Health (ARPA-H) to advance drug development using human data trials. The New Haven-based company will serve as technical lead for the project under ARPA-H's CATALYST programme. Revalia will develop AI-driven models trained on Human Data Trials, which use living systems derived from donated human organs, organ-on-chip platforms and multimodal datasets. The approach aims to reduce reliance on animal testing and better predict drug behaviour in humans, potentially cutting late-stage failures and accelerating therapy development. The company's Human Data Trial platform transforms donated organs into actionable insights for drug safety and efficacy predictions before clinical trials. CEO Greg Tietjen described the award as validation that "the era for human data is here".
- Revalia Bio Inc., a new pre-clinical research company secures $14.5M in seed funding round to support the launch of its "Human Data Trials".
Revalia Bio raised $14.5 million in a seed round to launch its Human Data Trials platform, which uses real human organs for pre-clinical research. The funding was co-led by America's Frontier Fund and Sierra Ventures. Revalia's approach aims to improve drug development accuracy and reduce costs by using data from perfused human organs. The company has quadrupled its revenue since 2023 and signed two top pharmaceutical companies as customers. Total funding now stands at $19.5 million.
Yale spinout Revalia Bio secures $14.5 million in seed funding to pioneer human data trials using perfusion technology, aiming to revolutionize drug development.
/PRNewswire/ -- The National Kidney Foundation (NKF) Innovation Fund is proud to announce its latest investment in Revalia Bio, an innovative health technology...
There are no jobs for Revalia Bio right now.
Find jobs on Simplify and start your career today
About Revalia Bio
Industries
Data & Analytics
Consulting
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Seed
Total Funding
$14.5M
Headquarters
New Haven, Connecticut
Founded
2022
There are no jobs for Revalia Bio right now.
Find jobs on Simplify and start your career today